Class ITerminatedD-1169-2014
Drug recall · March 26, 2014
Clalis capsules recall
Why: Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that the products was found to contain sildenafil, an undeclared active pharmaceutical ingredient.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Clalis capsules, 50 mg, 6 -count bottle ( labeling is in foreign language)
- Lots / codes
All lots
- Company
- Fabscout Entertainment, Inc, Ft Lauderdale, FL
- Distribution
- Nationwide and France
- Initiated
- June 27, 2013 · Voluntary: Firm initiated
- Classified
- March 20, 2014
- Reported
- March 26, 2014
- Ended
- October 2, 2019
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.